Covira Surgical, founded on the pioneering research of Dr. John Alverdy, MD, focuses on developing innovative drugs that modulate the gut microbiome to prevent post-surgical infections. The company’s core mission is to leverage the biological activity of resident bacteria in the gut to create novel therapeutics aimed at reducing surgical complications and improving patient outcomes. Covira’s primary market includes healthcare providers and institutions seeking advanced solutions for infection control and post-operative care.
Notable figures associated with Covira include Dr. John Alverdy, a renowned expert in the molecular basis of post-surgical infections. The company has garnered significant recognition, including being awarded Pepperdine Graziadio Business School's Most Fundable Companies® and featuring on the cover of Business Worldwide Magazine. These accolades highlight Covira's impact and potential in the biotech industry, particularly in enhancing surgical recovery through microbiome modulation.